Wellstat Therapeutics Corp. gained a rare pediatric disease priority review voucher (PRV) from the FDA with the agency's approval of Xuriden (uridine triacetate), a pyrimidine analogue for uridine replacement for the treatment of hereditary orotic aciduria (HOA), a potentially life-threatening disease known to impact fewer than 22 children worldwide.